Air Pollution, Brain, and Mind

Chronic urban air pollution measurably damages the brain and mind, and this paper lays out a concrete plan to catch that damage early — and to price the protection that urban green corridors might offer.

The core bet is this: we already know from epidemiology that long-term exposure to fine particulate matter (PM₂.₅) and nitrogen dioxide (NO₂) raises dementia risk by roughly 4–42% and depression/anxiety risk by 10–16%, depending on the study design. The biological story is coherent too — oxidative stress, neuroinflammation, blood-brain-barrier breakdown, amyloid accumulation. What's missing is the middle layer: human neurophysiological evidence, measured continuously in real people living real lives, that links ambient pollution to brain-network dysfunction before clinical disease appears. That's the gap this proposal targets.

The tool of choice is wearable EEG (brainwave recordings) plus actigraphy (wrist-worn movement/sleep trackers), deployed longitudinally across Madrid's natural pollution gradient — from heavily trafficked urban cores to the holm-oak woodlands of El Pardo and the proposed Northwest Ecological Corridor. The existing EEG literature is thin but suggestive: diesel exhaust shifts frontal brain activity toward fast-beta within 30 minutes; elevated PM₂.₅ suppresses the alpha-wave signature of focused attention; ozone degrades sleep architecture. A Madrid cohort of 200–500 participants, measured monthly over two to three years, would be the first study to track these signals longitudinally across a real city's exposure range, including a "protective arm" of participants who live or spend time in the green corridor.

The second half of the paper introduces REWILD-Madrid, a four-stage quantitative cascade designed to make the rewilding hypothesis financially underwritable. Stage one models how vegetation changes air chemistry (oak woodland absorbs PM₂.₅ but can worsen ozone locally — the paper is honest about this). Stage two fits the cohort's EEG and sleep data to exposure using Bayesian distributed-lag models. Stage three converts exposure changes to cases of dementia and depression averted, using WHO and EPA health-impact tools calibrated to Madrid's baseline disease rates. Stage four translates cases averted into euros saved — roughly €35,000–40,000 per dementia case per year — and computes a net present value per hectare rewilded over 30 years. The target audience for that final number is an insurance underwriter deciding whether to pay for ecological infrastructure as a health intervention.

The paper is explicitly a grant-scoping note, not a completed study, and it says so. The open-questions section is unusually candid: atmospheric modeling partners haven't been locked in, the exact EEG hardware needs piloting, and the full CHIMERE/MEGAN/i-Tree stack hasn't been run for Madrid before. What it delivers is a tightly reasoned research architecture — exposure model, cohort design, statistical framework, and financial translation — that connects a hectare of rewilded oak forest to a reduction in insured neurological claims.